Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis

Laboratory Investigation

Volumn 91, Issue 6, 2011, Pages 896-904

  Jing, Gu ^a   Yuan, Kaiyu ^a   Turk, Amy N ^a   Jhala, Nirag C ^a   Arnoletti, Juan P ^b   Zhang, Kui ^c   McDonald, Jay M ^a,d,e   Chen, Yabing ^a,d  

^a University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

apoptosis; cholangiocarcinoma; gemcitabine; tamoxifen; tumor xenograft

Indexed keywords

CASPASE; CASPASE 2; CASPASE 3; CASPASE 9; GEMCITABINE; REAGENT; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 79957608771     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.60     Document Type: Article

References (59)

1. Pitt HA, Dooley WC, Yeo CJ, et al. Malignancies of the biliary tree. Curr Probl Surg 1995;32:1-90.
2. Braconi C, Patel T. Cholangiocarcinoma: new insights into disease pathogenesis and biology. Infect Dis Clin North Am 2010;24:871-884.
3. Fava G, Marzioni M, Benedetti A, et al. Molecular pathology of biliary tract cancers. Cancer Lett 2007;250:155-167. (Pubitemid 46529440)
4. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472-477. (Pubitemid 38230849)
5. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-1314. (Pubitemid 41416587)
6. Mosconi S, Beretta GD, Labianca R, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol 2009;69:259-270.
7. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128:655-667.
8. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33: 1353-1357. (Pubitemid 32496970)
9. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16. (Pubitemid 27386911)
10. Ahn EY, Pan G, Oh JH, et al. The combination of calmodulin antagonists and interferon-g induces apoptosis through caspasedependent and -independent pathways in cholangiocarcinoma cells. Am J Pathol 2003;163:2053-2063. (Pubitemid 37310035)
11. Pawar P, Ma L, Byon CH, et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res 2009;15:1288-1296.
12. Pan G, Vickers SM, Pickens A, et al. Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. Am J Pathol 1999;155:193-203. (Pubitemid 29318717)
13. Vickers SM, Jhala NC, Ahn EY, et al. Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by g interferon (IFN-g). Ann Surg 2002;235:872-878. (Pubitemid 34547307)
14. Ahn EY, Pan G, Vickers SM, et al. IFN-gamma upregulates apoptosisrelated molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 2002;100:445-451.
15. Que FG, Phan VA, Phan VH, et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999;30:1398-1404.
16. Chen Y, Xu J, Jhala N, et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,30-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006;169:1833-1842. (Pubitemid 351182012)
17. Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971;25:270-275.
18. Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973;1:13-14.
19. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-477. (Pubitemid 33078758)
20. Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001;48:783-789. (Pubitemid 32619681)
21. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19:4089-4091. (Pubitemid 32976699)
22. Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005;103:111-118. (Pubitemid 39665463)
23. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-2338. (Pubitemid 46218726)
24. Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006;2:509-514. (Pubitemid 44304609)
25. André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR Study. Ann Oncol 2004;15:1339-1343. (Pubitemid 39295020)
26. Nabhan C, Gajria D, Krett NL, et al. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther 2002;1:1221-1227.
27. Huang P, Chubb S, Hertel LW, et al. Action of 20,20-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-6117.
28. Christgen M, Schniewind B, Jueschke A, et al. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells. Cancer Lett 2005;227:193-200. (Pubitemid 41169933)
29. Yu WD, Ma Y, Flynn G, et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 2010;15: 3022-3029.
30. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin. Cancer Res 2010;20:7970-7980.
31. da Silva GN, de Castro Marcondes JP, de Camargo EA, et al. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 2010;235:814-824.
32. Hall FM. Cisplatin plus gemcitabine for biliary tract cancer. N Engl J Med 2010;363:192-193.
33. Galvão FH, Pestana JO, Capelozzi VL. Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. Cancer Chemother Pharmacol 2010;65:607-610.
34. Ko E, Lee S, Goodman A. Gemcitabine pulmonary toxicity in ovarian cancer. Oncologist 2008;13:807-881.
35. Shaib W, Lansigan F, Cornfeld D, et al. Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. JOP 2008;9:708-714.
36. Barlé si F, Villani P, Doddoli C, et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85-91.
37. Ustundag Y, Bronk SF, Gores GJ. Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells. World J Gastroenterol 2007;13:851-857. (Pubitemid 46470294)
38. Sidi S, Sanda T, Kennedy RD, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008;133:864-877. (Pubitemid 351715394)
39. Dahal GR, Karki P, Thapa A, et al. Caspase-2 cleaves DNA fragmentation factor (DFF45)/inhibitor of caspase-activated DNase (ICAD). Arch Biochem Biophys 2007;468:134-139. (Pubitemid 350087845)
40. Krumschnabel G, Sohm B, Bock F, et al. The enigma of caspase-2: the laymen's view. Cell Death Differ 2009;16:195-207.
41. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42. (Pubitemid 43102075)
42. Hotchkiss RS, Strasser A, McDunn JE, et al. Cell death. N Engl J Med 2009;361:1570-1583.
43. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999;4:241-251.
44. Ferreira CG, Span SW, Peters GJ, et al. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the nonsmall cell lung cancer cell line NCI-H460. Cancer Res 2000;60:7133-7141. (Pubitemid 32059195)
45. Bandala E, Espinosa M, Maldonado V, et al. Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine. Biochem Pharmacol 2001;62:13-19. (Pubitemid 32488973)
46. Kitamura K, Minami Y, Yamamoto K, et al. Involvement of CD95- independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000;14:1743-1750.
47. Belka C, Marini P, Lepple-Wienhues A, et al. The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene 1999;18:4983-4992. (Pubitemid 29425305)
48. Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? Nat Rev Cancer 2009;9:897-903.
49. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002;297:1352-1354. (Pubitemid 34913174)
50. Lin CF, Chen CL, Chang WT, et al. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramide and etoposideinduced apoptosis. J Biol Chem 2004;279:40755-40761.
51. Lin CF, Chen CL, Chang WT, et al. Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J Biol Chem 2005;280:23758-23765.
52. Samraj AK, Sohn D, Schulze-Osthoff K, et al. Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization. Mol Biol Cell 2007;18:84-93. (Pubitemid 46066713)
53. Werner AB, Tait SW, de Vries E, et al. Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. J Biol Chem 2004;279:28771-28780. (Pubitemid 38900162)
54. McNamara DA, Harmey J, Wang JH, et al. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 2001;27:714-718. (Pubitemid 33085539)
55. Duffy SM, Lawley WJ, Kaur D, et al. Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. J Allergy Clin Immunol 2003;112:965-972. (Pubitemid 37412067)
56. Mabuchi S, Ohmichi M, Kimura A, et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 2004;145:1302-1313. (Pubitemid 38281014)
57. Jones JL, Daley BJ, Enderson BL, et al. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surg 2002;68:575-577. (Pubitemid 44897068)
58. Reddel RR, Sutherland RL. Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. Eur J Cancer Clin Oncol 1984;20:1419-1424. (Pubitemid 15202303)
59. Pace E, Melis M, Siena L, et al. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 2000;46:467-476.